Legal and regulatory update

Abstract

The Office of Fair Trading (OFT) has recently found Genzyme Limited guilty of abusing its dominant position in the market for the supply of drugs for the treatment of Gaucher disease in breach of the 'Chapter II prohibition' of the Competition Act 1998. Genzyme supplies a drug called Cerezyme, which until recently was the only treatment for Gaucher disease, a rare inherited genetic disorder. Owing to the serious nature of the infringement, the OFT fined Genzyme £6.8m.